The durability of sitagliptin in elderly patients with type 2 diabetes

The durability of sitagliptin in elderly patients with type 2 diabetes

Ching-Jung Hsieh, Feng-Chih Shen Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan Aim: To evaluate the durability of sitagli...

Full description

Bibliographic Details
Main Authors:	Hsieh CJ, Shen FC
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-11-01
Series:	Clinical Interventions in Aging
Subjects:	Type 2 diabetes Sitagliptin Oral anti-diabetic drugs Dipeptidyl peptidase IV inhibitor
Online Access:	https://www.dovepress.com/the-durability-of-sitagliptin-in-elderly-patients-withnbsptype-2-diabe-peer-reviewed-article-CIA

Similar Items

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01)

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
by: Shih-Yi Lin, et al.
Published: (2018-06-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Noncardiac pulmonary edema induced by sitagliptin treatment
by: Tahir Belice, et al.
Published: (2014-01-01)

Effects of treatment with sitagliptin on hepatotoxicity induced by acetaminophen in mice
by: Wafaa Ahmed Hewedy
Published: (2021-04-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
by: Soon Ae Kim, et al.
Published: (2011-04-01)

Transcriptomic Analysis Reveals That Retinal Neuromodulation Is a Relevant Mechanism in the Neuroprotective Effect of Sitagliptin in an Experimental Model of Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022-12-01)

Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study
by: Tomoyuki Saito, et al.
Published: (2020-06-01)

Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2021-11-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms
by: Qamraa H. Alqahtani, et al.
Published: (2023-12-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022-07-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
by: Yuya Tsurutani, MD, PhD, et al.
Published: (2017-01-01)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
by: Mee Kyoung Kim, et al.
Published: (2023-08-01)

Inhibitory effects of selected cannabinoids against dipeptidyl peptidase IV, an enzyme linked to type 2 diabetes
by: Lithalethu Mkabayi, et al.
Published: (2024-01-01)

Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
by: Sachiko Hattori
Published: (2021-10-01)

Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
by: Patricia Bogdanov, et al.
Published: (2022-02-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
by: Sung-Ho Kim, et al.
Published: (2016-09-01)

Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity
by: Yudi Purnomo, et al.
Published: (2015-08-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
by: Dimitrios Patoulias, et al.
Published: (2021-08-01)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
by: Sae Jeong Yang, et al.
Published: (2021-07-01)

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
by: Young-Hwan Park, et al.
Published: (2024-03-01)

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
by: Jun Sung Moon, et al.
Published: (2023-11-01)

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
by: Geert Jan Biessels, et al.
Published: (2018-01-01)

Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
by: Pankaj M. Kharabe, et al.
Published: (2024-08-01)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
by: Xiao-jun Zhou, et al.
Published: (2019-03-01)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
by: Yoshia Miyawaki, et al.
Published: (2018-10-01)

Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing
by: Gisela Schott, et al.
Published: (2017-10-01)

Computational Modeling of the Interactions between DPP IV and Hemorphins
by: Priya Antony, et al.
Published: (2024-03-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)